Qiagen N.V.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan M. Pratt
- Full Time Employees
- 5,654
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Hulsterweg 82 Venlo LI Netherlands 5912 PL
- IPO Date
- Jun 28, 1996
- CIK
- 0001015820
- Website
- qiagen.com
- Similar Companies
- Business
- QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA) provides Sample to Insight solutions that enable molecular diagnostics, applied testing, academic and pharmaceutical research, and bioinformatics through products and services for extracting, analyzing and interpreting insights from DNA, RNA and proteins. The company offers sample technologies including kits, consumables and automated instruments for nucleic acid isolation and processing from blood, tissue and other materials; assay technologies such as PCR, next-generation sequencing (NGS) panels like QIAseq xHYB Long Read Panels for structural variants, HLA typing and repeat expansions, multiplex real-time PCR systems like QIAstat-Dx, and immunoassay platforms like QuantiFERON for latent TB detection; bioinformatics software and knowledge bases for data interpretation; and automation solutions including QIAmini, QIAsprint Connect and QIAsymphony Connect for high-throughput workflows. Founded in 1984 and headquartered in Venlo, Netherlands, with main operational headquarters in Hilden, Germany, and regional offices in the United States, China and Singapore, QIAGEN serves over 500,000 customers worldwide including academia, pharma/biotech R&D, clinical labs, forensics, veterinary and food safety sectors across more than 35 countries. In recent developments, QIAGEN acquired Parse Biosciences in November 2025 for $225 million upfront plus up to $55 million in milestones to enter the single-cell sequencing market supporting AI-driven biology; announced a $500 million synthetic share repurchase to complete in early January 2026 as part of over $1 billion in shareholder returns since 2024; launched QIAseq xHYB Long Read Panels in 2025 to enhance NGS target enrichment; exceeded Q3 2025 financial outlook with raised full-year adjusted EPS guidance; and advanced launches of three new sample preparation instruments in 2025-2026 targeting liquid biopsy, oncology and high-throughput applications.
Company News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Block, Constellation Energy, Dick’s Sporting Goods, Dutch Bros, Halliburton Company, Netflix, Southern Company,Tesla, and More
QIAGEN reports preliminary Q3 2026 results
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.93 According to Brokerages
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
15,494 Shares of Qiagen N.V. $QGEN Bought by Cordatus Wealth Management LLC
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
Qiagen N.V. $QGEN Shares Sold by Envestnet Asset Management Inc.
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
A Look at Qiagen NV (QGEN) After 3.4% Gain -- GF Value $49.88 vs Price $44.78
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript